• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Area under the curve"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-20 of 22

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study 

      Briassoulis, E. Ch; Kalofonos, H. P.; Bafaloukos, Dimitrios; Samantas, E.; Fountzilas, George; Xiros, N.; Skarlos, Dimosthenis V.; Christodoulou, C.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2000)
      Purpose: To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP). Patients and Methods: Seventy-seven consecutive CUP patients (45 women and 32 men; median ...

    • Article  

      Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer 

      Samantas, E.; Skarlos, Dimosthenis V.; Pectasides, Dimitrios; Nikolaidis, Pavlos; Kalofonos, H. P.; Mylonakis, N.; Vardoulakis, Th; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Fountzilas, George (1999)
      Sixty patients with poor prognostic features, either with extensive disease (ED) or limited disease (LD) small cell lung cancer (SCLC), were treated on an out-patient basis with Carboplatin 80 mg/m2 weekly for 3 weeks and ...

    • Article  

      Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: A phase III randomized study. Preliminary results 

      Kosmidis, Paraskevas A.; Mylonakis, N.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Samantas, E.; Dimitriadis, K.; Kalofonos, H. P.; Tsavdaridis, D.; Skarlos, Dimosthenis V. (2000)
      Gemcitabine plus paclitaxel and paclitaxel plus carboplatin are active and well tolerated in patients with advanced non-small cell lung cancer, showing similar rates of response and survival. The Hellenic Cooperative ...

    • Article  

      Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study 

      Pentheroudakis, George; Briassoulis, E. Ch; Kalofonos, H. P.; Fountzilas, George; Economopoulos, T.; Samelis, G.; Koutras, A. K.; Karina, M.; Xiros, N.; Samantas, E.; Bamias, A. T.; Pavlidis, Nicholas (2008)
      Introduction. Taxane/platinum combinations exhibit synergistic cytotoxicity and activity against a broad range of solid tumours. We sought to optimise the regimen as a suitable outpatient palliative treatment for cancer ...

    • Article  

      Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction 

      Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Piperidou, C.; Soulti, K.; Pavlidis, Nicholas (2006)
      The aim of this study is to investigate the feasibility and determine the pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. This was a prospective study. Patients with liver ...

    • Article  

      Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in patients with advanced gastrointestinal carcinomas: A phase I dose-finding and pharmacokinetic study 

      Bamias, A. T.; Syrigos, K.; Fountzilas, George; Tzamakou, E.; Soulti, K.; Karavasilis, V.; Alamanos, Y. P.; Christodoulou, C.; Pavlidis, Nicholas (2004)
      5-Fluorouracil (5FU) and cisplatin are commonly used in the treatment of gastric cancer. Continuous 5FU appears to be more effective and less toxic than bolus administration, while increasing the dose intensity of cisplatin ...

    • Article  

      Interaction pharmacokinetis of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel 

      Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Soulti, K.; Piperidou, C.; Pavlidis, Nicholas (2004)
      Purpose: To investigate the pharmacokinetics of polyethylene glycol-coated liposomal doxorubicin (PLD, Caelyx) when given as a single agent and in combination with the taxanes paclitaxel or docetaxel in humans. Methods: ...

    • Article  

      Laboratory Assessment of the Anticoagulant Activity of Dabigatran 

      Kyriakou, Elias; Ikonomidis, Ignatios; Stylos, D.; Bonovas, Stefanos; Papadakis, I.; Nikolopoulos, Georgios K.; Kokoris, Styliani; Kalantzis, Dimitrios; Economopoulou, Christine; Kopterides, Petros; Lekakis, John; Tsantes, Argirio E. (2015)
      Background: Our aim was to identify laboratory assays in order to assess the anticoagulant effects of dabigatran etexilate (DE). Methods: Twenty patients with nonvalvular atrial fibrillation treated on DE (110 mg per os ...

    • Article  

      Multicentre phase II pharmacological evaluation of rhizoxin 

      McLeod, H. L.; Murray, L. S.; Wanders, J.; Setanoians, A.; Graham, M. A.; Pavlidis, Nicholas; Heinrich, B.; Huinink, W. W. Ten Bokkel; Wagener, D. J. Th; Aamdal, S.; Verweij, J. (1996)
      Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines and xenograft models. ...

    • Article  

      Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: A phase I/II study conducted by the Hellenic Cooperative Oncology Group 

      Fountzilas, George; Pectasides, Dimitrios; Kalogera-Fountzila, Anna; Skarlos, Dimosthenis V.; Kalofonos, H. P.; Papadimitriou, C.; Bafaloukos, Dimitrios; Lambropoulos, S.; Papadopoulos, S.; Kourea, H.; Markopoulos, C.; Linardou, H.; Mavroudis, D.; Briassoulis, E. Ch; Pavlidis, Nicholas; Razi, E. D.; Kosmidis, Paraskevas A.; Gogas, H. (2005)
      Paclitaxel (TaxolR) and carboplatin are an effective combination regimen for treating advanced breast cancer. Gefitinib (IRESSA) is the first epidermal growth factor receptor tyrosine kinase inhibitor to be approved for ...

    • Article  

      Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck: A phase II study conducted by the Hellenic Cooperative Oncology Group 

      Fountzilas, George; Skarlos, Dimosthenis V.; Athanasiades, A.; Kalogera-Fountzila, Anna; Samantas, E.; Bacoyiannis, Charalambos; Nicolaou, A.; Dombros, N.; Briassoulis, E. Ch; Dinopoulou, M.; Stathopoulos, G. P.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Daniilidis, J. (1997)
      Background: Paclitaxel has been demonstrated to have significant activity in recurrent or metastatic head and neck cancer (HNC). In addition, the combination of paclitaxel and cisplatin is active in untreated patients with ...

    • Article  

      Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: Long-term efficacy results: A Hellenic Cooperative Oncology Group (HeCOG) study 

      Aravantinos, Gerasimos; Fountzilas, George; Kosmidis, Paraskevas A.; Dimopoulos, M. A.; Stathopoulos, G. P.; Pavlidis, Nicholas; Bafaloukos, Dimitrios; Papadimitriou, C.; Karpathios, S.; Georgoulias, V.; Papakostas, P.; Kalofonos, H. P.; Grimani, E.; Skarlos, Dimosthenis V. (2005)
      Background: We compared the combination plus Carboplatin plus paclitaxel, which is considered the treatment of choice for initial chemotherapy of advanced ovarian cancer (AOC) with a regimen combining alternating carboplatin ...

    • Article  

      Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: Preliminary results of a Hellenic Cooperative Ontology Group study 

      Skarlos, Dimosthenis V.; Aravantinos, Gerasimos; Kosmidis, Paraskevas A.; Athanasiades, A.; Stathopoulos, G. P.; Pavlidis, Nicholas; Bafaloukos, Dimitrios; Karpathios, S.; Papakostas, P.; Bamia, C.; Fountzilas, George (1997)
      Ninety previously untreated patients with advanced epithelial ovarian cancer (International Federation of Gynecology and Obstetrics stages IIC, III, and IV) were randomized, after initial cytoreductive surgery, to receive ...

    • Article  

      Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: Accumulating evidence for synergy, efficacy, and safety 

      Pentheroudakis, George; Razi, E. D.; Athanasiades, A.; Pavlidis, Nicholas; Fountzilas, George (2006)
      Patients with metastatic breast cancer receive multiple lines of cytotoxic chemotherapy, with taxane and anthracycline-based regimens being the most active. Anthracyclines carry the risk of significant cardiotoxicity at ...

    • Article  

      Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: Results of a dose-escalation study 

      Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Haidou, C.; Piperidou, C.; Pavlidis, Nicholas (2002)
      We characterized the toxicity and determined the maximum tolerated dose of non-break weekly paclitaxel (Taxol) in chemotherapy-naive cancer patients, and studied pharmacokinetics of the formulation vehicle Cremophor-EL ...

    • Article  

      Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study 

      Pappas, P.; Karavasilis, V.; Briassoulis, E. Ch; Pavlidis, Nicholas; Marselos, M. (2005)
      Aim: To evaluate the pharmacokinetics of imatinib mesylate (Glivec) and its main metabolite (CGP74588) in a patient with end stage renal disease on hemodialysis and compare it with published data from subjects with normal ...

    • Article  

      Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group 

      Briassoulis, E. Ch; Judson, Ian Robert; Pavlidis, Nicholas; Beale, P.; Wanders, J.; Groot, Y.; Veerman, G.; Schuessler, M.; Niebch, G.; Siamopoulos, K. C.; Tzamakou, E.; Rammou, D.; Wolf, L.; Walker, R.; Hanauske, A. R. (2000)
      Purpose: To determine the maximum-tolerated dose (MTD), the principal toxicities, and the pharmacokinetics of 6-hour infusion of glufosfamide (beta-D-glucosylisophosphoramide mustard; D-19575), a novel alkylating agent ...

    • Article  

      Phase i trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: A hellenic cooperative oncology group study 

      Briassoulis, E. Ch; Golfinopoulos, Vassilis; Karina, M.; Papakostas, P.; Pavlidis, Nicholas; Fountzilas, George (2010)
      This trial aimed to define a recommended safe dose (RSD) of weekly paclitaxel and irinotecan combined with carboplatin in patients with advanced cancer. Patients with advanced cancer were eligible for this trial. Dose-limiting ...

    • Article  

      Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9 

      Schellens, J. H. M.; Dombernowsky, P.; Cassidy, J.; Epelbaum, R.; Dirix, L.; Cox, E. H.; Wanders, J.; Calabresi, F.; Paridaens, R.; Monfardini, S.; Wolff, J.; Loos, W. J.; Verweij, J.; Pavlidis, Nicholas; Hanauske, A. R. (2001)
      Population pharmacokinetic-dynamic analysis was prospectively integrated in the clinical phase II programme of EO9 to determine the population pharmacokinetic profile in a larger population of patients, to estimate individual ...

    • Article  

      Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG 

      Joerger, M.; Huitema, A. D. R.; Richel, D. J.; Dittrich, C.; Pavlidis, Nicholas; Briassoulis, E. Ch; Vermorken, J. B.; Strocchi, E.; Martoni, A.; Sorio, R.; Sleeboom, H. P.; Izquierdo, M. A.; Jodrell, D. I.; Féty, R.; Bruijn, E. De; Hempel, G.; Karlsson, M.; Tranchand, B.; Schrijvers, A. H. G. J.; Twelves, C.; Beijnen, J. H.; Schellens, J. H. M. (2007)
      Aims: To investigate the population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients. Patients and methods: Sixty-five female patients with early or advanced breast cancer ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD